2Delauche-Cavallier MC, Chaufour S, Guerault E, et al. QT interval monitoring during clinical studies with mizolastine, a new H1 Antihistamine[J]. Clin Exp Allergy, 1999, 29 Suppl 3:206-211.
二级参考文献10
1Craft TM. Torsade de pointes after astemizole overdose[J]. Br Med J (Clin Res Ed), 1986, 292(6521): 660.
2Monahan BP, Ferguson CL, Killeavy ES, et al. Torsades de pointes occurring in association with terfenadine use[J]. JAMA, 1990, 264(21): 2788-2790.
3Venturini E, Borghi E, Maurini V, et al. Prolongation of the Q-T interval and hyperkinetic ventricular arrhythmias probably induced by terfenadine use in liver cirrhosis patients[J]. Recenti Prog Med,1992, 83(1): 21-22.
4Dubertret L, Murrieta Aguttes M, Tonet J. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study[J]. J Eur Acad Dermatol Venereol, 1999, 12(1): 16-24.
5Chaufour S, Caplain H, Lilienthal N, et al. Study of cardiac repolarization in healthy volunteers performed with mizolastine, a new HI-receptor antagonist[J]. Br J Clin Pharmacol, 1999, 47(5):515-520.
6Lorette G, Giannetti A, Pereira RS, et al. One-year treatment of chronic urticaria with mizolastine: efficacy and safety. URTOL study group[J]. J Eur Acad Dermatol Venereol, 2000, 14(2): 83-90.
7Honig PK, Wortham DC, Zamani K, et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences[J]. JAMA, 1993, 269(12): 1513-1518.
8Honig PK, Woosley RL, Zamani K, et al. Changes in the phannacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin[J]. Clin Pharmacol Ther, 1992, 52(3): 231-238.
9Lebrun-Vignes B, Diquet B, Chosidow O. Clinical pharmacokinetics of mizolastine[J]. Clin Pharmacokinet, 2001, 40(7): 501-507.
10Delauche-Cavallier MC, Chaufour S, Guerault E, et al. QT interval monitoring during clinical studies with mizolastine, a new Hi antihistamine[J]. Clin Exp Allergy, 1999, 29( Suppl 3): 206-211.
